

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:06:35 ON 27 JUL 2004

=> fil .bec,canc

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILES 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS, NTIS, ESBIODBASE, BIOTECHNO, WPIDS, CANCERLIT' ENTERED AT 09:06:52 ON 27 JUL 2004
ALL COPYRIGHTS AND RESTRICTIONS APPLY. SEE HELP USAGETERMS FOR DETAILS.

12 FILES IN THE FILE LIST

=> s carboxylesterase#

FILE 'MEDLINE'

L1 2027 CARBOXYLESTERASE#

FILE 'SCISEARCH'

L2 1454 CARBOXYLESTERASE#

FILE 'LIFESCI'

L3 710 CARBOXYLESTERASE#

FILE 'BIOTECHDS'

L4 201 CARBOXYLESTERASE#

FILE 'BIOSIS'

L5 1774 CARBOXYLESTERASE#

FILE 'EMBASE'

L6 1788 CARBOXYLESTERASE#

FILE 'HCAPLUS'

L7 2556 CARBOXYLESTERASE#

FILE 'NTIS'

L8 57 CARBOXYLESTERASE#

FILE 'ESBIODBASE'

L9 548 CARBOXYLESTERASE#

FILE 'BIOTECHNO'

L10 566 CARBOXYLESTERASE#

FILE 'WPIDS'

L11 57 CARBOXYLESTERASE#

FILE 'CANCERLIT'

L12 244 CARBOXYLESTERASE#

TOTAL FOR ALL FILES

L13 11982 CARBOXYLESTERASE#

=> s cpt-11 or irinotecan

FILE 'MEDLINE'

3907 CPT

550723 11

1138 CPT-11

(CPT(W) 11)

2124 IRINOTECAN

L14 2295 CPT-11 OR IRINOTECAN

```

FILE 'SCISEARCH'
    4625 CPT
    451789 11
    1317 CPT-11
        (CPT(W) 11)
    1730 IRINOTECAN
L15      2140 CPT-11 OR IRINOTECAN

FILE 'LIFESCI'
    587 "CPT"
    72669 "11"
    74 CPT-11
        ("CPT" (W) "11")
    62 IRINOTECAN
L16      110 CPT-11 OR IRINOTECAN

FILE 'BIOTECHDS'
    55 CPT
    31373 11
    16 CPT-11
        (CPT(W) 11)
    36 IRINOTECAN
L17      43 CPT-11 OR IRINOTECAN

FILE 'BIOSIS'
    3845 CPT
    494851 11
    1141 CPT-11
        (CPT(W) 11)
    1460 IRINOTECAN
L18      1958 CPT-11 OR IRINOTECAN

FILE 'EMBASE'
    4267 "CPT"
    345726 "11"
    1697 CPT-11
        ("CPT" (W) "11")
    4336 IRINOTECAN
L19      4385 CPT-11 OR IRINOTECAN

FILE 'HCAPLUS'
    4497 CPT
    839085 11
    931 CPT-11
        (CPT(W) 11)
    1394 IRINOTECAN
L20      1855 CPT-11 OR IRINOTECAN

FILE 'NTIS'
    525 CPT
    73219 11
    1 CPT-11
        (CPT(W) 11)
    1 IRINOTECAN
L21      1 CPT-11 OR IRINOTECAN

FILE 'ESBIOBASE'
    1819 CPT
    140714 11
    583 CPT-11
        (CPT(W) 11)
    853 IRINOTECAN
L22      1060 CPT-11 OR IRINOTECAN

```

FILE 'BIOTECHNO'
899 CPT
86517 11
311 CPT-11
(CPT(W)11)
651 IRINOTECAN
L23 675 CPT-11 OR IRINOTECAN

FILE 'WPIDS'
363 CPT
1462208 11
99 CPT-11
(CPT(W)11)
236 IRINOTECAN
L24 303 CPT-11 OR IRINOTECAN

FILE 'CANCERLIT'
1751 CPT
153379 11
1160 CPT-11
(CPT(W)11)
1549 IRINOTECAN
L25 1831 CPT-11 OR IRINOTECAN

TOTAL FOR ALL FILES
L26 16656 CPT-11 OR IRINOTECAN

=> s 113 and 126
FILE 'MEDLINE'
L27 90 L1 AND L14

FILE 'SCISEARCH'
L28 120 L2 AND L15

FILE 'LIFESCI'
L29 8 L3 AND L16

FILE 'BIOTECHDS'
L30 6 L4 AND L17

FILE 'BIOSIS'
L31 100 L5 AND L18

FILE 'EMBASE'
L32 106 L6 AND L19

FILE 'HCAPLUS'
L33 93 L7 AND L20

FILE 'NTIS'
L34 0 L8 AND L21

FILE 'ESBIOBASE'
L35 73 L9 AND L22

FILE 'BIOTECHNO'
L36 40 L10 AND L23

FILE 'WPIDS'
L37 4 L11 AND L24

FILE 'CANCERLIT'
L38 66 L12 AND L25

TOTAL FOR ALL FILES
L39 706 L13 AND L26

=> s l39 and py<=1999 range=2003,
FILE 'MEDLINE'
'2003,' IS NOT A VALID RANGE FOR FILE 'MEDLINE'
SEARCH ENDED BY USER

FILE 'SCISEARCH'
207 PY<=1999
L40 0 L28 AND PY<=1999

FILE 'LIFESCI'
732 PY<=1999
L41 0 L29 AND PY<=1999

FILE 'BIOTECHDS'
64 PY<=1999
(PY<=1999)
L42 0 L30 AND PY<=1999

FILE 'BIOSIS'
3866 PY<=1999
L43 0 L31 AND PY<=1999

FILE 'EMBASE'
208 PY<=1999
L44 0 L32 AND PY<=1999

FILE 'HCAPLUS'
3968 PY<=1999
L45 0 L33 AND PY<=1999

FILE 'NTIS'
3135 PY<=1999
L46 0 L34 AND PY<=1999

FILE 'ESBIOBASE'
0 PY<=1999
L47 0 L35 AND PY<=1999

FILE 'BIOTECHNO'
1285569 PY<=1999
L48 19 L36 AND PY<=1999

FILE 'WPIDS'
9972 PY<=1999
(PY<=1999)
L49 0 L37 AND PY<=1999

FILE 'CANCERLIT'
0 PY<=1999
L50 0 L38 AND PY<=1999

TOTAL FOR ALL FILES
L51 19 L39 AND PY<=1999

=> fil medl
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
17.00	17.21

FILE 'MEDLINE' ENTERED AT 09:09:49 ON 27 JUL 2004

=> s l39 and py<=1999 range=2003000000,
16758 PY<=1999
L52 1 L27 AND PY<=1999

=> d

L52 ANSWER 1 OF 1 MEDLINE on STN
TI Pharmacology of **irinotecan**.
S0 Drugs of today (Barcelona, Spain : 1998), (1998 Sep) 34 (9)
777-803.
Journal code: 101160518. ISSN: 0025-7656.
AU Robert J; Rivory L
AN 2004097687 MEDLINE

=> fil .becpat
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.43	17.64

FILES 'BIOTECHDS, HCAPLUS, WPIDS' ENTERED AT 09:10:23 ON 27 JUL 2004
ALL COPYRIGHTS AND RESTRICTIONS APPLY. SEE HELP USAGETERMS FOR DETAILS.

3 FILES IN THE FILE LIST

=> s l39 and wo/pc and pry<=1999 range=2003,
FILE 'BIOTECHDS'

12395 WO/PC
1059 PRY<=1999
(PRY<=1999)

L53 0 L30 AND WO/PC AND PRY<=1999

FILE 'HCAPLUS'

83340 WO/PC
15050 PRY<=1999

L54 1 L33 AND WO/PC AND PRY<=1999

FILE 'WPIDS'

182739 WO/PC
74029 PRY<=1999
(PRY<=1999)

L55 0 L37 AND WO/PC AND PRY<=1999

TOTAL FOR ALL FILES

L56 1 L39 AND WO/PC AND PRY<=1999

=> d

L56 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Use of bi-specific antibodies for pre-targeting diagnosis and therapy
SO U.S. Pat. Appl. Publ., 59 pp., Cont.-in-part of U.S. Ser. No. 823,746.
CODEN: USXXCO
IN Goldenberg, David M.; Hansen, Hans J.; Leung, Shui-on; McBride, William
J.; Qu, Zhengxing
AN 2003:836381 HCAPLUS
DN 139:341719

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003198595	A1	20031023	US 2002-150654	20020517 <--
US 2002006379	A1	20020117	US 2001-823746	20010403 <--
WO 2003097105	A1	20031127	WO 2003-GB2110	20030516 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
 PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
 TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
 NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, ML, MR, NE, SN, TD, TG

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

8.78

26.42

STN INTERNATIONAL LOGOFF AT 09:11:54 ON 27 JUL 2004

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	543	carboxylesterase\$1	US-PGPUB; USPAT	OR	OFF	2004/07/27 09:03
L2	10526	cpt-11 or (cpt adj "11") or apc	US-PGPUB; USPAT	OR	OFF	2004/07/27 09:03
L3	2474	camptothecin	US-PGPUB; USPAT	OR	OFF	2004/07/27 09:03
L4	151	1 same (2 or 3)	US-PGPUB; USPAT	OR	OFF	2004/07/27 09:03
L5	28	rabbit same 1	US-PGPUB; USPAT	OR	OFF	2004/07/27 09:04
L6	6	4 and 5	US-PGPUB; USPAT	OR	OFF	2004/07/27 09:04

PGPUB-DOCUMENT-NUMBER: 20040115688

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040115688 A1

TITLE: Detection of gd2 synthase mrna and uses thereof

PUBLICATION-DATE: June 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cheung, Irene Y.	Purchase	NY	US	
Cheung, Nai-King V	Purchase		GB	

APPL-NO: 10/ 477435

DATE FILED: November 7, 2003

PCT-DATA:

APPL-NO: PCT/US02/15037

DATE-FILED: Apr 19, 2002

PUB-NO:

PUB-DATE:

371-DATE:

102(E)-DATE:

US-CL-CURRENT: 435/6

ABSTRACT:

The present invention provides a method to measure GD2 synthase mRNA comprising steps of: (a) obtaining a mRNA sample; (b) performing real-time quantitative RT-PCR on the sample using appropriate primers of GD2 synthase; and (c) determining the amount of GD2 synthase mRNA. The invention also provides a method to diagnose a subject which bears cancer expressing GD2 synthase. Furthermore, this invention provides a method to stage a cancer expressing GD2 synthase in a subject. Finally, this invention provides a kit for detection of GD2 synthase.

[0001] This application claims priority of U.S. Ser. No. 60/290,527, filed 11 May 2001, the content of which is incorporated by reference here into this application.

----- KWIC -----

Detail Description Paragraph - DETX (282):

[0304] Autologous marrow/stem cell transplantation is an integral part of the curative strategy for refractory cancers like neuroblastoma (NB)..sup.1 Clearly tumor-free harvests are of critical importance, since genetically marked tumor cells in autologous bone marrow were demonstrated to be present at site of disease relapse in NB and AML..sup.2, 3 A variety of in vitro methods have been explored to purge tumor cells of diverse origin. Chemical purging utilizes chemotherapeutic agents such as 4-hydroperoxycyclophosphamide,.sup.4

and mafosfamide. .sup.5 Immunomagnetic depletion of tumor cells exploits the tagging of tumor-reactive monoclonal antibody (MoAb) to antimouse IgG-coated magnetic polystyrene microspheres..sup.6-8 Complement-mediated purging takes advantage of unique MoAb that can activate the complement cascade in sensitive tumors..sup.9, 10 Photoradiation of tumor cells is another method for purging autologous bone marrow grafts..sup.11 More recently, selection of antigen CD34-positive stem cells has become an attractive method to deplete tumor cells from peripheral blood stem cells (PBSC) because this antigen is only expressed on early lymphohematopoietic stem cells and progenitor cells, and not on mature blood cells or on tumor cells..sup.12, 13 A relatively recent development in bone marrow purging is the use of viral-directed enzyme prodrug..sup.14 Adenovirus was utilized to deliver the cDNA encoding a rabbit liver carboxylesterase that activates the prodrug CPT-11 to its active form SN-38 in NB cell lines efficiently.

Detail Description Paragraph - DETX (328):

[0346] 14. Meck M M, Wierdl M, Wagner L M, Burger R A, Guichard S M, Krull E J, et al. A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11. Cancer Res 2001;61:5083-89.